Want to see GNLX full AI Analyst Report?
Genelux Corp. (GNLX) Drug Pipeline
| Drug Name | Condition | Stage | Status | Study Name | Trial Start Date | Article |
|---|---|---|---|---|---|---|
| Docetaxel, Olvimulogene Nanivacirepvec, Platinum Chemotherapy: Carboplatin Or Cisplatin, Non-Platinum Chemotherapy: Paclitaxel Or Nab-Paclitaxel For Squamous Cell Nsclc Or Pemetrexed For Nonsquamous Cell Nsclc, Physician's Choice Of Immune Checkpoint Inhibitor: Pembrolizumab, Nivolumab, Cemiplimab, Atezolizumab, Durvalumab | Non-small Cell Lung Cancer, Non-Small Cell Lung Cancer Stage Iv, Non-Small Cell Lung Cancer Stage Iii, Non-Small Cell Lung Cancer Recurrent, Advanced Non-Squamous Non-Small-Cell Lung Cancer, Advanced Squamous Non-Small Cell Lung Carcinoma, Metastatic Non-Squamous Non Small Cell Lung Cancer, Metastatic Squamous Non-Small Cell Lung Carcinoma | Phase II | Recruiting | Efficacy & Safety of Olvimulogene Nanivacirepvec & Platinum-doublet + Physician's Choice of Immune Checkpoint Inhibitor Compared to Docetaxel in NSCL Cancer | Jun 11, 2024 | ― |
| Olvimulogene Nanivacirepvec, Platinum Chemotherapy: Carboplatin (Preferred) Or Cisplatin, Non-Platinum Chemotherapy: Physician's Choice Of Gemcitabine, Taxane (Paclitaxel, Docetaxel Or Nab-Paclitaxel) Or Pegylated Liposomal Doxorubicin, Bevacizumab (Or Biosimilar) | Fallopian Tube Cancer, Platinum-Resistant Ovarian Cancer, High-Grade Serous Ovarian Cancer, Primary Peritoneal Cancer, Ovarian Clear Cell Carcinoma, Platinum-Refractory Ovarian Cancer, Endometrioid Ovarian Cancer | Phase III | Recruiting | Efficacy & Safety of Olvi-Vec and Platinum-doublet + Bevacizumab Compared to Physician's Choice of Chemotherapy and Bevacizumab in Platinum-Resistant/Refractory Ovarian Cancer (PRROC) (OnPrime, GOG-3076) | Mar 07, 2022 | ― |
| Gl-Onc1 | Peritoneal Carcinomatosis | phase1AndPhase2 | Completed | A Study of GL-ONC1, an Oncolytic Vaccinia Virus, in Patients With Advanced Peritoneal Carcinomatosis | Sep 20, 2011 | ― |
| Gl-Onc1 | Advanced Cancers (Solid Tumors) | Phase I | Completed | Safety Study of GL-ONC1, an Oncolytic Virus, in Patients With Advanced Solid Tumors | Nov 18, 2008 | ― |
| Drug Name | Stage | Condition | Status | Study Name | Trial Start Date | Article |
|---|---|---|---|---|---|---|
| Docetaxel, Olvimulogene Nanivacirepvec, Platinum Chemotherapy: Carboplatin Or Cisplatin, Non-Platinum Chemotherapy: Paclitaxel Or Nab-Paclitaxel For Squamous Cell Nsclc Or Pemetrexed For Nonsquamous Cell Nsclc, Physician's Choice Of Immune Checkpoint Inhibitor: Pembrolizumab, Nivolumab, Cemiplimab, Atezolizumab, Durvalumab | Phase II | Non-small Cell Lung Cancer, Non-Small Cell Lung Cancer Stage Iv, Non-Small Cell Lung Cancer Stage Iii, Non-Small Cell Lung Cancer Recurrent, Advanced Non-Squamous Non-Small-Cell Lung Cancer, Advanced Squamous Non-Small Cell Lung Carcinoma, Metastatic Non-Squamous Non Small Cell Lung Cancer, Metastatic Squamous Non-Small Cell Lung Carcinoma | Recruiting | Efficacy & Safety of Olvimulogene Nanivacirepvec & Platinum-doublet + Physician's Choice of Immune Checkpoint Inhibitor Compared to Docetaxel in NSCL Cancer | Jun 11, 2024 | ― |
| Olvimulogene Nanivacirepvec, Platinum Chemotherapy: Carboplatin (Preferred) Or Cisplatin, Non-Platinum Chemotherapy: Physician's Choice Of Gemcitabine, Taxane (Paclitaxel, Docetaxel Or Nab-Paclitaxel) Or Pegylated Liposomal Doxorubicin, Bevacizumab (Or Biosimilar) | Phase III | Fallopian Tube Cancer, Platinum-Resistant Ovarian Cancer, High-Grade Serous Ovarian Cancer, Primary Peritoneal Cancer, Ovarian Clear Cell Carcinoma, Platinum-Refractory Ovarian Cancer, Endometrioid Ovarian Cancer | Recruiting | Efficacy & Safety of Olvi-Vec and Platinum-doublet + Bevacizumab Compared to Physician's Choice of Chemotherapy and Bevacizumab in Platinum-Resistant/Refractory Ovarian Cancer (PRROC) (OnPrime, GOG-3076) | Mar 07, 2022 | ― |
| Gl-Onc1 | phase1AndPhase2 | Peritoneal Carcinomatosis | Completed | A Study of GL-ONC1, an Oncolytic Vaccinia Virus, in Patients With Advanced Peritoneal Carcinomatosis | Sep 20, 2011 | ― |
| Gl-Onc1 | Phase I | Advanced Cancers (Solid Tumors) | Completed | Safety Study of GL-ONC1, an Oncolytic Virus, in Patients With Advanced Solid Tumors | Nov 18, 2008 | ― |
FAQ
What are the FDA phases for drug approval?
The FDA approval process for new drugs is divided into several phases: a. Preclinical testing b. Phase 1 – Safety and dosage c. Phase 2 – Effectiveness and side effects d. Phase 3 – Confirmation of effectiveness, monitoring of adverse reactions, and comparison with existing treatments e. Phase 4 – Post-marketing studies to track long-term safety and effectiveness
What is a clinical trial?
A clinical trial is a carefully designed study in which researchers test a drug, treatment, or medical device in people to evaluate its safety, effectiveness, and potential side effects. These trials are essential for determining whether a new treatment should be approved for widespread use.
What drugs does Genelux Corp. (GNLX) have in its pipeline
Genelux Corp. GNLX is currently developing the following drugs: Docetaxel, Olvimulogene Nanivacirepvec, Platinum Chemotherapy: Carboplatin Or Cisplatin, Non-Platinum Chemotherapy: Paclitaxel Or Nab-Paclitaxel For Squamous Cell Nsclc Or Pemetrexed For Nonsquamous Cell Nsclc, Physician's Choice Of Immune Checkpoint Inhibitor: Pembrolizumab, Nivolumab, Cemiplimab, Atezolizumab, Durvalumab, Olvimulogene Nanivacirepvec, Platinum Chemotherapy: Carboplatin (Preferred) Or Cisplatin, Non-Platinum Chemotherapy: Physician's Choice Of Gemcitabine, Taxane (Paclitaxel, Docetaxel Or Nab-Paclitaxel) Or Pegylated Liposomal Doxorubicin, Bevacizumab (Or Biosimilar), Gl-Onc1. These drug candidates are in various stages of clinical development as the company works toward FDA approval.
